How does a protein called connexin put the clamps on cancer?
Researchers in the School of Medicine at The University of Texas Health Science Center at San Antonio today reported an explanation.
Study senior author Jean X. Jiang, Ph.D., professor of biochemistry at the Health Science Center, said connexin tethers itself to a cell-proliferating molecule called Skp2.
This prevents the Skp2 from travelling to the cell nucleus to promote more cell growth, she said.
The majority of cells in the body have connexin proteins, but primary tumours have very low amounts.
"This is because the presence of connexins suppresses primary tumour growth," Dr. Jiang said.
Dr. Jiang and her team study the eye lens, which is rich in connexin proteins, as a model system to understand how connexin functions in cells throughout the body.
First author of the study is Qian Shi, Ph.D., a postdoctoral fellow at the Health Science Center.
"If there is a way to amplify the presence of connexin, then there can be a way to suppress the cell proliferation, for example in cancer," Dr. Jiang said.
In the future, cancer therapies could potentially be based on connexin molecules, the study suggests.
The journal Developmental Cell published the findings online.
Dr. Jiang's research is funded by a five-year, $1.6 million grant from the National Eye Institute of the U.S. National Institutes of Health.
Source: University Of Texas Health Science Center At San Antonio
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.